Inflammatory response in blood driving factor

Several pipettes above vessels provided for this purpose

Inflammatory response in blood driving factor

{post_date}  •  {terms}

11. July 2022  •  Diagnostics

What factors influence the life expectancy of patients with advanced gastric cancer? Scientists at Leipzig University Hospital have discovered that the body’s inflammatory response is accompanied by reduced muscle quality in patients and ultimately constitutes the decisive factor for the prognosis. Their results have been published in the “Annals of Oncology”.

A research group at Leipzig University Hospital, led by Professor Ulrich Hacker, together with scientists from Masaryk University in Brno, Czech Republic, has investigated what influences the life expectancy of patients with advanced gastric cancer. The evaluation included data from over 500 individuals who had been treated within a clinical trial several years ago.

Their analysis used certain values in the blood that indicate an inflammatory response in the body, as well as measurements of muscle quality. “From our findings, it can be concluded that in aggressive, advanced tumour diseases, as exemplified by gastric carcinoma, the inflammatory response in the blood is the driving factor for disease progression. This is closely related to the development of sarcopenia, a loss of muscle mass and quality,” explains Professor Hacker, senior physician at Leipzig University Hospital. The physicians also found that in patients who underwent chemotherapy as part of the trial and in whom the disease had not progressed further, the inflammation level measured in the blood decreased significantly.

When it comes to prognosis, scientific discussions have so far attached great importance to muscle parameters. This has given rise to the hypothesis that measures to improve tumour patients’ muscles could in turn improve their life expectancy. At least for advanced tumour diseases, as in the present study, it now appears that the inflammatory response is a leading factor.

“We demonstrate that blood inflammation levels and sarcopenia are closely related. Contrary to our findings in a previous study, we now know that muscle quality is not a decisive factor for the life expectancy of patients with advanced gastric cancer,” Professor Hacker explains, summarising the key message of the research. He adds: “Influencing the inflammatory response is emerging as a key target to improve both prognosis and sarcopenia.”

To treat sarcopenia, experts often suggest physical training and, above all, dietary changes. “However, it is also known that dietary changes do not work well when elevated inflammatory markers are detected in the blood. This new study data suggests that effective tumour therapy reduces inflammatory responses, which could lay a good foundation for effective nutritional interventions,” says Professor Hacker. Future studies would have to clarify whether the findings could be transferred to other tumour types and how different tumour therapies or other treatments affect inflammatory responses in the blood.

“Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial.” DOI:10.1016/j.annonc.2022.03.274

Author: Anne Grimm

More

First in Europe: All approved CAR-T cell therapy products are available at the University Hospital Leipzig (UKL).

Small glas bottle which is normally used to store vaccine

cell-immune-gene-therapies

Small glas bottle which is normally used to store vaccine

Chimeric Antigen Receptor T Cell Therapy (CAR-T): Genetically programmed immune cell binds to and destroys cancer cell / Therapy is now available for the majority of indications

Smart Infrastructure Hub in Leipzig receives a further 1,9 million euros in funding

Human who looks onto a recording of brainwaves on his tablet computer and moves the model with his fingers

digital-health

Human who looks onto a recording of brainwaves on his tablet computer and moves the model with his fingers

The Smart Infrastructure Hub Leipzig will receive a further 1,9 million euros from the cluster funding of the Saxon Ministry of Economic Affairs.

BIO-Europe 2022 in Leipzig/Saxony breaks records

Small glas bottle which is normally used to store vaccine

cell-immune-gene-therapies

Small glas bottle which is normally used to store vaccine

A relatively small metropolis in Germany’s Free State of Saxony – a dynamic hub for the life science industry? What was just a vision 20 years ago has become a reality for the city of Leipzig, which from October 24-26 co-hosted BIO-Europe, Europe’s largest annual biotech partnering event.

Back to top